Shares of OvaScience Inc. (NASDAQ:OVAS) saw strong trading volume on Wednesday . 768,113 shares were traded during mid-day trading, an increase of 111% from the previous session’s volume of 364,743 shares.The stock last traded at $7.96 and had previously closed at $7.44.

Several research analysts recently weighed in on the stock. JPMorgan Chase & Co. decreased their price objective on shares of OvaScience from $9.00 to $8.00 and set a “neutral” rating on the stock in a research report on Friday, August 5th. JMP Securities restated a “neutral” rating on shares of OvaScience in a research report on Wednesday, August 10th. Zacks Investment Research upgraded shares of OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Wednesday, August 10th. Finally, Credit Suisse Group AG restated a “sell” rating on shares of OvaScience in a research report on Tuesday, July 12th. One analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $10.98.

The stock has a 50-day moving average of $6.41 and a 200 day moving average of $7.17. The stock’s market cap is $290.18 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/ovascience-inc-ovas-sees-strong-trading-volume.html

OvaScience (NASDAQ:OVAS) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.62) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.16. OvaScience had a negative return on equity of 60.10% and a negative net margin of 13,906.35%. The company had revenue of $0.19 million for the quarter, compared to analysts’ expectations of $0.21 million. During the same period in the previous year, the firm earned ($0.64) EPS. The firm’s revenue was up 530.0% compared to the same quarter last year. On average, equities analysts forecast that OvaScience Inc. will post ($2.66) EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Oppenheimer & Co. Inc. boosted its stake in shares of OvaScience by 1.0% in the second quarter. Oppenheimer & Co. Inc. now owns 52,112 shares of the company’s stock valued at $271,000 after buying an additional 517 shares during the period. Parametric Portfolio Associates LLC boosted its stake in shares of OvaScience by 11.4% in the second quarter. Parametric Portfolio Associates LLC now owns 39,431 shares of the company’s stock valued at $205,000 after buying an additional 4,038 shares during the period. Nationwide Fund Advisors boosted its stake in shares of OvaScience by 31.8% in the second quarter. Nationwide Fund Advisors now owns 20,068 shares of the company’s stock valued at $105,000 after buying an additional 4,846 shares during the period. ProShare Advisors LLC boosted its stake in shares of OvaScience by 28.7% in the second quarter. ProShare Advisors LLC now owns 29,507 shares of the company’s stock valued at $154,000 after buying an additional 6,572 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in shares of OvaScience by 2.8% in the first quarter. JPMorgan Chase & Co. now owns 341,789 shares of the company’s stock valued at $3,243,000 after buying an additional 9,350 shares during the period. 80.70% of the stock is currently owned by institutional investors and hedge funds.

OvaScience Company Profile

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

5 Day Chart for NASDAQ:OVAS

Receive News & Ratings for OvaScience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience Inc. and related companies with MarketBeat.com's FREE daily email newsletter.